search
Back to results

Pre- vs Postoperative Thromboprophylaxis for Liver Resection (PREPOSTEROUS)

Primary Purpose

Liver Cancer, Surgery, Thrombosis, Deep Vein

Status
Recruiting
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
enoxaparin or tinzaparin or dalteparin
No intervention
Sponsored by
Helsinki University Central Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Liver Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All patients undergoing liver resection

Exclusion Criteria:

  • Patient on anticoagulative medication (heparin, low-molecular weight heparin, warfarin, direct oral anticoagulants) during last month pre-surgery
  • Emergency operation (e.g. for trauma or infection)
  • Age < 18 years
  • Allergy or other contraindication to planned low-molecular weight heparin
  • Inability to give written informed consent
  • Liver resection not performed (removed from analyses after randomization)

Sites / Locations

  • Helsinki University HospitalRecruiting
  • Kuopio University HospitalRecruiting
  • Oulu University Hospital
  • Tampere University HospitalRecruiting
  • Turku University Hospital
  • Oslo University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Preoperative thromboprophylaxis

Postoperative thromboprophylaxis

Arm Description

Preoperatively initiated tromboprophylaxis

Postoperatively initiated thromboprophylaxis

Outcomes

Primary Outcome Measures

Venous thromboembolisms
Number of patients with venous thromboembolism defined as either 1) symptomatic deep venous thromboembolism (includes all deep veins e.g. all extremities, portal vein, and superior mesenteric) diagnosed using ultrasound or computed tomography or magnetic resonance imaging, or in re-laparatomy/surgery, 2) pulmonary embolism diagnosed using computed tomography, magnetic resonance imaging, or lung perfusion imaging, or 3) death due to venous thromboembolism

Secondary Outcome Measures

Posthepatectomy haemorrhage
Number of patients with posthepatectomy haemorrhage, any grade in ISGLS classification
Postoperative complications
Comprehensive Complication Index - score
Length of postoperative hospital stay
Length of postoperative hospital stay, days
Blood transfusion
Total amount of transfused red blood cells, units

Full Information

First Posted
January 26, 2021
Last Updated
September 21, 2022
Sponsor
Helsinki University Central Hospital
Collaborators
Academy of Finland, The Finnish Medical Association
search

1. Study Identification

Unique Protocol Identification Number
NCT04731558
Brief Title
Pre- vs Postoperative Thromboprophylaxis for Liver Resection
Acronym
PREPOSTEROUS
Official Title
Pre- vs Postoperative Thromboprophylaxis for Liver Resection - a Prospective, Multicenter, Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 10, 2021 (Actual)
Primary Completion Date
February 2025 (Anticipated)
Study Completion Date
March 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Helsinki University Central Hospital
Collaborators
Academy of Finland, The Finnish Medical Association

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Thromboprophylaxis for liver surgery can be commenced either preoperatively or postoperatively. Despite a clear trade-off between thrombosis and bleeding in liver surgery patients, there is no international consensus when thrombosis prophylaxis should be commenced in patients undergoing liver surgery. As far as we know, there are no prospective randomized trials in this field, and current guidelines are unfortunately based on very low quality evidence, that is, a few retrospective studies and expert opinion. Both American and European thromboprophylaxis guidelines for abdominal cancer surgery support the preoperative initiation of thromboprophylaxis, but these guidelines do not specifically address the increased bleeding risk associated with liver surgery. On the contrary, Dutch guidelines recommend postoperative thromboprophylaxis only, because of lack of evidence for preoperative thromboprophylaxis. Traditionally, many liver surgery units have been reluctant in using preoperative thromboprophylaxis due to the potentially increased risk of bleeding complications. Enhanced Recovery After Surgery (ERAS) Society Guidelines recommend preoperative thromboprophylaxis in liver surgery, but the guidelines provide no supporting evidence for this recommendation. Overall, the amount of evidence is scarce and somewhat contradictory in this clinically relevant field of thromboprophylaxis in liver surgery. The aim of this study is to compare pre- and postoperatively initiated thromboprophylaxis regimens in liver surgery in a randomized controlled trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Cancer, Surgery, Thrombosis, Deep Vein, Embolism, Pulmonary, Bleeding

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1012 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Preoperative thromboprophylaxis
Arm Type
Experimental
Arm Description
Preoperatively initiated tromboprophylaxis
Arm Title
Postoperative thromboprophylaxis
Arm Type
Other
Arm Description
Postoperatively initiated thromboprophylaxis
Intervention Type
Drug
Intervention Name(s)
enoxaparin or tinzaparin or dalteparin
Intervention Description
Thromboprophylaxis initiated approximately 14 hours prior to the planned liver resection skin incision. Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function
Intervention Type
Drug
Intervention Name(s)
No intervention
Intervention Description
No preoperative thromboprophylaxis.
Primary Outcome Measure Information:
Title
Venous thromboembolisms
Description
Number of patients with venous thromboembolism defined as either 1) symptomatic deep venous thromboembolism (includes all deep veins e.g. all extremities, portal vein, and superior mesenteric) diagnosed using ultrasound or computed tomography or magnetic resonance imaging, or in re-laparatomy/surgery, 2) pulmonary embolism diagnosed using computed tomography, magnetic resonance imaging, or lung perfusion imaging, or 3) death due to venous thromboembolism
Time Frame
within 30 days from liver resection
Secondary Outcome Measure Information:
Title
Posthepatectomy haemorrhage
Description
Number of patients with posthepatectomy haemorrhage, any grade in ISGLS classification
Time Frame
within 30 days from liver resection
Title
Postoperative complications
Description
Comprehensive Complication Index - score
Time Frame
within 30 days from liver resection
Title
Length of postoperative hospital stay
Description
Length of postoperative hospital stay, days
Time Frame
within 30 days from liver resection
Title
Blood transfusion
Description
Total amount of transfused red blood cells, units
Time Frame
during and within 30 days from liver resection

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients undergoing liver resection Exclusion Criteria: Patient on anticoagulative medication (heparin, low-molecular weight heparin, warfarin, direct oral anticoagulants) during last month pre-surgery Emergency operation (e.g. for trauma or infection) Age < 18 years Allergy or other contraindication to planned low-molecular weight heparin Inability to give written informed consent Liver resection not performed (removed from analyses after randomization)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ville Sallinen, MD, PhD
Phone
+358-9-4711
Email
ville.sallinen@helsinki.fi
Facility Information:
Facility Name
Helsinki University Hospital
City
Helsinki
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aki Uutela, MD
Phone
+358-9-4711
Email
aki.uutela@hus.fi
Facility Name
Kuopio University Hospital
City
Kuopio
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pekka Lammi, MD
Email
pekka.lammi@kys.fi
Facility Name
Oulu University Hospital
City
Oulu
Country
Finland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Heikki Karjula, MD, PhD
Email
heikki.karjula@ppshp.fi
Facility Name
Tampere University Hospital
City
Tampere
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yrjö Vaalavuo, MD
Email
yrjo.vaalavuo@pshp.fi
Facility Name
Turku University Hospital
City
Turku
Country
Finland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maija Lavonius, MD
Email
maija.lavonius@tyks.fi
Facility Name
Oslo University Hospital
City
Oslo
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sheraz Yaqib, MD
Email
shya@ous-hf.no

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Pre- vs Postoperative Thromboprophylaxis for Liver Resection

We'll reach out to this number within 24 hrs